The use of thrombolytic therapy in a multidisciplinary pulmonary embolism response team

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


Introduction: The implementation of a pulmonary embolism response team (PERT) is associated with an increase in the use of thrombolysis, in particular, catheter-directed thrombolysis (CDT). Expert multidisciplinary PERTs may use thrombolysis outside of guideline recommendations, but the clinical characteristics of patients treated with thrombolysis by PERT clinicians are not well described. Materials and methods: This study was based on all confirmed pulmonary embolism (PE) patients within the MGH PERT database as of January 1st, 2019. Patients were stratified according to treatment strategy and divided into patients having received any thrombolytic treatment (AT), CDT, intravenous thrombolysis (IVT) or no clot reducing therapy (NCR). Data were extracted on demographics, symptoms, medical history, clot burden, right heart strain, biochemistry and operational characteristics. Furthermore, patients were risk-stratified according to ESC guidelines. Univariate analyzes were performed for three different comparisons; AT vs NCR, CDT vs NCR and CDT vs IVT. Results: Among confirmed PE patients, 109/831 (13.1%) underwent thrombolytic therapy. Thrombolysis was divided between 74 (8.9%) CDT and 35 (4.2%) IVT. Central clot burden (p ​< ​0.001), right heart strain (p ​< ​0.001), and abnormal vital signs (p ​< ​0.001) were strongly correlated to thrombolytic therapy. CDT was favored over IVT in patients within the ESC intermediate-high risk category (p ​< ​0.001), with central thrombus (p ​= ​0.028) and during weekdays (p ​= ​0.028). Conclusions: In this retrospective analysis, we identified several factors associated with the choice of treatment within the MGH PERT program. These data may be useful in understanding how patients are chosen for thrombolysis and whether different thrombolytic approaches improve outcomes in PE.

TidsskriftThrombosis Update
StatusUdgivet - jan. 2021

Bibliografisk note

Funding Information:
The work was supported by the Novo Nordisk Foundation [ NNF18OC0032968 ]; and Eva og Henry Frænkels Mindefond. Funders were not involved in any aspect of the study including its design; collection, analysis, and interpretation of the data; or the writing and submission of the manuscript.

Publisher Copyright:
© 2021 The Authors

Se relationer på Aarhus Universitet Citationsformater

ID: 268610768